U.S. Peripheral Vascular Devices Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Market Overview

The U.S. Peripheral Vascular Devices Market is anticipated to grow from USD 2,945.00 million in 2023 to USD 4,947.26 million by 2032, registering a compound annual growth rate (CAGR) of 6.70%.

Growth in this market is primarily driven by the increasing incidence of peripheral artery diseases (PAD) and the expanding geriatric demographic—both significant contributors to vascular health complications. Technological progress, including the adoption of minimally invasive procedures and the evolution of device engineering, is enhancing treatment outcomes and safety, fueling market demand. A heightened emphasis on early diagnosis and preventive care is accelerating the uptake of peripheral vascular devices. The emergence of bioresorbable technologies and a shift toward outpatient vascular interventions are reshaping care delivery models. Innovations in materials and the advancement of next-generation stents and catheters are further improving therapeutic efficacy. Additionally, favorable reimbursement frameworks and increased healthcare investment are creating a supportive environment for broader device utilization. Collectively, these factors are expected to sustain market growth over the forecast period.

Market Drivers

Aging Demographics and Healthcare Spending Growth

A key market driver is the aging U.S. population, which is increasingly prone to vascular disorders such as PAD. By 2034, the population aged 65 and older is projected to exceed 77 million, significantly boosting demand for vascular interventions. This demographic shift, coupled with rising healthcare expenditures and enhanced access to medical services, is fostering greater adoption of peripheral vascular devices. These trends are expanding treatment accessibility, thereby accelerating market growth.

Market Challenges Analysis

High Cost of Advanced Peripheral Vascular Devices

The high cost associated with peripheral vascular devices remains a significant challenge for market expansion. Cutting-edge interventions, including stents, balloons, and catheters, entail extensive R&D and regulatory processes, resulting in elevated production costs. For example, the development of new stent technologies requires comprehensive clinical validation and approval, which contributes to pricing pressures. These expenses are frequently transferred to healthcare providers and patients, limiting affordability—particularly for those with limited or no insurance coverage. Although increased demand may offset some financial burdens, the introduction of premium technologies such as bioresorbable stents and drug-eluting devices intensifies the cost barrier, constraining widespread adoption.

Market Segmentation

By Type:

Angioplasty Balloons

Angioplasty Stents

Catheters

Guidewires

Others

By End-User:

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

By Geography:

Western United States

Midwestern United States

Southern United States

Northeastern United States

Key Player Analysis

Abbott Laboratories

Boston Scientific Corporation

Medtronic plc

Terumo Corporation

Becton, Dickinson and Company

Cardinal Health

Cook Medical

Koninklijke Philips N.V.

AngioDynamics, Inc.

Biotronik SE & Co. KG